enGene Therapeutics Inc. - Common Shares (ENGN)

CUSIP: 29286M105

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Shares
Shares outstanding
67,348,192
Total 13F shares
31,657,538
Share change
+17,469,674
Total reported value
$536,055,932
Price per share
$16.95
Number of holders
31
Value change
+$295,887,521
Number of buys
24
Number of sells
5

Quarterly Holders Quick Answers

What is CUSIP 29286M105?
CUSIP 29286M105 identifies ENGN - enGene Therapeutics Inc. - Common Shares in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of ENGN - enGene Therapeutics Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
FCPM III SERVICES B.V.
13F
Company
mixed-class rows
12,556,099
mixed-class rows
$82,543,914 31 Dec 2023
13F
Lumira Capital Investment Management Inc.
3/4/5
10%+ Owner
class O/S missing
3,849,299
$38,492,990 20 Feb 2024
BVF INC/IL
13F
Company
mixed-class rows
3,196,439
mixed-class rows
$21,580,664 31 Dec 2023
13F
Blue Owl Capital Holdings LP
13F
Company
mixed-class rows
1,709,837
mixed-class rows
$11,800,650 31 Dec 2023
13F
Omega Fund Management, LLC
13F
Company
mixed-class rows
1,606,252
mixed-class rows
$10,844,560 31 Dec 2023
13F
Vivo Capital, LLC
13F
Company
1%
678,705
$6,264,447 31 Dec 2023
13F
Polar Asset Management Partners Inc.
13F
Company
mixed-class rows
297,665
mixed-class rows
$1,276,884 31 Dec 2023
13F
ROYAL BANK OF CANADA
13F
Company
0.06%
37,845
$349,000 31 Dec 2023
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.06%
37,447
$345,636 31 Dec 2023
13F
Saba Capital Management, L.P.
13F
Company
class O/S missing
230,470
$270,802 31 Dec 2023
13F
Calamos Advisors LLC
13F
Company
class O/S missing
250,000
$212,500 31 Dec 2023
13F
CITADEL ADVISORS LLC
13F
Company
0.03%
20,057
$185,126 31 Dec 2023
13F
COWEN AND COMPANY, LLC
13F
Company
class O/S missing
138,712
$117,905 31 Dec 2023
13F
AQR Arbitrage LLC
13F
Company
class O/S missing
127,339
$108,238 31 Dec 2023
13F
TENOR CAPITAL MANAGEMENT Co., L.P.
13F
Company
class O/S missing
116,666
$99,166 31 Dec 2023
13F
D. E. Shaw & Co., Inc.
13F
Company
class O/S missing
104,722
$89,014 31 Dec 2023
13F
PERISCOPE CAPITAL INC.
13F
Company
class O/S missing
100,000
$85,000 31 Dec 2023
13F
Atalaya Capital Management LP
13F
Company
class O/S missing
66,666
$56,666 31 Dec 2023
13F
Shaolin Capital Management LLC
13F
Company
class O/S missing
50,000
$42,500 31 Dec 2023
13F
Exos TFP Holdings LLC
13F
Company
class O/S missing
35,491
$30,167 31 Dec 2023
13F
KIM, LLC
13F
Company
class O/S missing
33,333
$28,333 31 Dec 2023
13F
WHITEBOX ADVISORS LLC
13F
Company
class O/S missing
33,333
$28,333 31 Dec 2023
13F
ARISTEIA CAPITAL, L.L.C.
13F
Company
class O/S missing
24,045
$28,253 31 Dec 2023
13F
CLEAR STREET LLC
13F
Company
class O/S missing
28,410
$24,149 31 Dec 2023
13F
CSS LLC/IL
13F
Company
class O/S missing
27,000
$22,950 31 Dec 2023
13F
STATE OF WISCONSIN INVESTMENT BOARD
13F
Company
class O/S missing
23,570
$20,035 31 Dec 2023
13F
UBS Group AG
13F
Company
0%
1,937
$17,879 31 Dec 2023
13F
Sculptor Capital LP
13F
Company
class O/S missing
11,300
$13,278 31 Dec 2023
13F
Walleye Capital LLC
13F
Company
class O/S missing
11,200
$9,520 31 Dec 2023
13F
WOLVERINE ASSET MANAGEMENT LLC
13F
Company
class O/S missing
5,633
$4,788 31 Dec 2023
13F
MORGAN STANLEY
13F
Company
0%
8
$74 31 Dec 2023
13F
Forbion Growth Sponsor FEAC I B.V.
3/4/5
10%+ Owner
mixed-class rows
5,502,338
mixed-class rows
31 Oct 2023
Forbion Capital Fund III Cooperatief U.A.
3/4/5
10%+ Owner
class O/S missing
2,894,735
31 Oct 2023
Jason David Hanson
3/4/5
Chief Executive Officer, Director
class O/S missing
512,826
31 Oct 2023
Richard P. Bryce
3/4/5
Chief Medical Officer
class O/S missing
153,000
30 Nov 2023
James C. Sullivan
3/4/5
Chief Scientific Officer
class O/S missing
118,509
31 Oct 2023
BVF PARTNERS L P/IL
3/4/5
10%+ Owner
class O/S missing
104,257
31 Oct 2023

Institutional Holders of enGene Therapeutics Inc. - Common Shares (ENGN) as of Q1 2024

As of 31 Mar 2024, enGene Therapeutics Inc. - Common Shares (ENGN) was held by 31 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 31,657,538 shares. The largest 10 holders included FCPM III SERVICES B.V., VR Adviser, LLC, Blue Owl Capital Holdings LP, BVF INC/IL, Deep Track Capital, LP, COMMODORE CAPITAL LP, ADAGE CAPITAL PARTNERS GP, L.L.C., Omega Fund Management, LLC, JANUS HENDERSON GROUP PLC, and Cormorant Asset Management, LP. This page lists 31 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders
11
Q1 2024 holders
31
Holder diff
20
Investor Q4 2023 Shares Q1 2024 Shares Share Diff Share Chg % Q4 2023 Value $ Q1 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .